GMP-compliant T cell activation with
MACS® GMP T Cell TransAct™

  • Safe and efficient GMP-compliant T cell activation
  • Highest quality and ready-to-use reagent
  • Exact volumetric dosage delivers consistent and reliable results
  • Can be sterile filtered

MACS GMP T Cell TransAct can be utilized in clinical applications for robust activation and expansion of human T cells. T Cell TransAct is a polymeric nanomatrix conjugated to humanized recombinant CD3 and CD28 agonists, ensuring efficient activation of T cells.

For complete regulatory notes click here.

Discover key advantages of MACS GMP T Cell TransAct

A table showing high actication levels of CD69 and CD25 after two days using MACS GMP T Cell TransAct compared to a low activation level  with the negative control.
Higher marker activation efficiency of T Cell TransAct compared to the negative control.

Efficient stimulation and expansion of T cells

By providing robust and effective GMP-compliant T cell activation, MACS GMP T Cell TransAct enables safe and streamlined clinical manufacturing for cell therapy.

The reagent delivers optimal T cell activation with a polymeric nanomatrix. For robust and reliable T cell proliferation, it facilitates serum-free T cell cultivation while maintaining consistently high cell expansion.

As shown in the graph, T cell activation was assessed by quantifying the expression of activation markers, CD25 and CD69, both in the absence and presence of MACS GMP T Cell TransAct. Remarkably, over 80% of the cells showed activation within two days when treated with TransAct, indicated in blue.

A table showing ascending lines in black, with serum and blue without serum to illustrate the high expansion and survial rates of T cells afer stimulation with MACS GMP T Cell TransAct.
After stimulation with MACS GMP T Cell TransAct, excellent T cell expansion and survival is observed regardless of serum content.

Excellent T cell expansion and survival even without serum

Clinical-scale expansion of transduced T cells is effective under cultivation conditions with or without human AB serum.
In both cases, cell numbers and viability remain high, even when measured for approximately two weeks. The synergistic combination of MACS GMP T Cell TransAct, TexMACS™ GMP Medium, and MACS® GMP Cytokines delivers an optimal engineered cell product independent of serum addition.

A dot-plot illustration shows transduction of T cells with GFP vector which resulted in strong GFP expression eleven days after gene modification. Two dotplots with untransduced T cells show no expression of GFP.
Transduction of T cells with GFP vector results in strong GFP encoding vectors.

Designed for GMP-compliant CAR T cell production

Compatible with CliniMACS Prodigy®, MACS GMP T Cell TransAct stimulates and activates CAR (Chimeric Antigen Receptor)T cells.

As part of the process T cells were stimulated with MACS GMP T Cell TransAct and transduced with two viral vectors encoding for GFP. Transduction of T cells with GFP vector resulted in strong GFP expression eleven days after gene engineering. To achieve long-term gene expression through stable genomic insertion, two types of gene transduction tools are commonly used: gamma-retroviral vectors (RV) or lentiviral vectors (LV).

The CliniMACS Prodigy T Cell Transduction (TCT) process supports transduction with both vectors. For easy integration of RV-based transduction into the automated workflow of the CliniMACS Prodigy TCT process, MACS® GMP Vectofusin®-1 enhances your viral transduction efficiency.

Image taken with a mircoscoic camera shows cluster formation of activated CD4+ and CD8+ T cells from a helathy and a melanoma patient. Two images show the cluster 72 hours after activation compared to 24h after activation with MACS GMP Cell Culture Products.
Cluster formation of activated CD4+ and CD8+ T cells from a healthy donor and a melanoma patient.

Microscopic analysis demonstrates strong T cell proliferation

Stable activation of T cells can be observed by microscopic analysis.

The image depicts CD4+/CD8+ T cells enriched from a healthy donor and a melanoma patient activated by the use of MACS GMP T Cell TransAct reagent. After 72 hours, the cell clumps in both the healthy donor and the melanoma patient indicate proper activation of the T cells.

Safety - Compliance

Two lab workers handlinging the ClinMACS Prodigy

Sterility and safety

MACS GMP T cell TransAct is manufactured and tested under a quality management system (ISO 13485) and is in compliance with relevant GMP guidelines. It is designed following the recommendations of USP <1043> on ancillary materials. The manufacturing and testing of this product is compliant with the requirements laid down in the Ph.Eur. Chapter 5.2.12. Learn more about our MACS GMP Products.

Every production step takes place under strict safety regulations in our GMP-certified facility, which is equipped with state of the art production areas from class A to D. MACS GMP T Cell TransAct is bottled using a validated aseptical filling process, before being subjected to a rigorous quality control (QC) testing procedure, thus guaranteeing a safe and sterile product. Every processing step from development to production and QC testing is extensively documented.

Tailored for closed workflows for T cell manufacturing

Overview of the CliniMACS Prodigy T Cell Transduction (TCT) including all steps.
Overview of the CliniMACS Prodigy T Cell Transduction (TCT).

MACS GMP T Cell TransAct is optimized for automated cell culture processes such as clinical-grade CAR T cell manufacturing with the CliniMACS Prodigy System.

This process allows fully automated labeling, enrichment, activation, transduction, and expansion of human T cells from patient material for production of gene-engineered T cells.

Learn more

Highlight references for clinical-grade CAR T cell manufacturing

Automated T cell transduction, using MACS GMP T Cell TransAct reagent, meets the requirements for clinical cell manufacturing.
Lock, D. & Mockel-Tenbrinck, N. et al. (2017) Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum. Gene Ther. 10: 914–925. https://doi: 10.1089/hum.2017.111

Successful CAR-T cell production in multiple clinical sites, with CliniMACS Prodigy System.
Maschan, M. et al. (2021) Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun. 12 (1): 7200. https://doi: 10.1038/s41467-021-27312-6

Feasibility of 27 CAR-T cell manufacturing products from individual patients, using CliniMACS Prodigy.
Castella, M. et al. (2020) Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: Experience from an academic phase I clinical trial. Front. Immunol. 11: 482. https://doi.org/10.3389/fimmu

MACS®GMP T Cell TransAct™ Products

Available in two fill sizes:

  • MACS® GMP T Cell TransAct™ : Optimized to expand 1×10⁸ enriched T cells.
  • MACS® GMP T Cell TransAct™ Large Scale: Optimized to expand 4×10⁸ enriched T cells.

1 product found

|

You have previously chosen International as your location.
What do you want to do?